| [1] |
Takanori K, Bin-Zhi Q, Pollard JW. Immune cell promotion of metastasis[J]. Nature Reviews Immunology, 2015, 15(2):73-86.
|
| [2] |
郭亮，吴炅.肿瘤患者外周血免疫细胞在疗效预测及预后价值中的研究进展[J].中华乳腺病杂志(电子版)，2018，12(5)：299-301.
|
| [3] |
李婵，吴远鹏，吴吉进，等.SII预测恶性实体肿瘤预后的研究进展[J].实用医院临床杂志，2018，15(3)：252-254.
|
| [4] |
Bo H, Xin-Rong Y, Yang X, et al. Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma[J]. Clin Cancer Res, 2014, 20(23):6212-6222.
|
| [5] |
周文杰，吴骏，王琦，等.评估术前系统免疫炎症指数与贲门癌患者预后的相关性[J].中国医药生物技术，2016，11(6)：510-514.
|
| [6] |
Zhong JH, Huang DH, Chen ZY. Prognostic role of systemic immune-inflammation index in solid tumors: a systematic review and meta-analysis[J]. Oncotarget, 2017, 8(43):75381-75388.
|
| [7] |
Hong X, Cui B, Wang M, et al. Systemic immune-inflammation index, based on platelet counts and neutrophil-lymphocyte ratio, is useful for predicting prognosis in small cell lung cancer[J]. Tohoku J Exp Med, 2015, 236(4):297.
|
| [8] |
Lolli C, Basso U, Derosa L, et al. Systemic immune-inflammation index predicts the clinical outcome in patients with metastatic renal cell cancer treated with sunitinib[J]. Oncotarget, 2016, 7(34):54564-54571.
|
| [9] |
Xianchun M, Qian C, Yuying L, et al. Determinant roles of gender and age on SII, PLR, NLR, LMR and MLR and their reference intervals defining in Henan, China: A posteriori and big-data-based[J]. J Clin Lab Anal, 2018, 32(2). doi: 10.1002/jcla.22228. |
| [10] |
Jingeng L, Xuan X, Chao Z, et al. Which factors are associated with actual 5-year survival of oesophageal squamous cell carcinoma[J]. Eur J Cardiothorac Surg, 2012, 41(3):e7.
|
| [11] |
Wang L, Wang C, Wang J, et al. A novel systemic immune-inflammation index predicts survival and quality of life of patients after curative resection for esophageal squamous cell carcinoma[J]. J Cancer Res Clin Oncol, 2017, 143(10):1-10.
|
| [12] |
耿晓如，张鑫君，李连涛，等.系统免疫炎症指数与老年食管癌预后的关系[J].徐州医科大学学报，2017，39(12)：779-782.
|
| [13] |
Huang L, Liu S, Lei Y, et al. Systemic immune-inflammation index, thymidine phosphorylase and survival of localized gastric cancer patients after curative resection[J]. Oncotarget, 2016, 7(28):44185-44193.
|
| [14] |
Chen L, Yan Y, Zhu L, et al. Systemic immune-inflammation index as a useful prognostic indicator predicts survival in patients with advanced gastric cancer treated with neoadjuvant chemotherapy[J]. Cancer Manag Res, 2017, 9:9849-867.
|
| [15] |
Wang K, Diao F, Ye Z, et al. Prognostic value of systemic immune-inflammation index in patients with gastric cancer[J]. Chin J Cancer, 2017, 36(1):75.
|
| [16] |
Cha C, Fong Y, Jarnagin WR. Predictors and patterns of recurrence after resection of hepatocellular carcinoma[J]. J Am Coll Surg, 2003, 197(5):753-758.
|
| [17] |
Hongyuan F, Jun Z, Jianye C, et al. Systemic immune-inflammation index (SII) is useful to predict survival outcomes in patients after liver transplantation for hepatocellular carcinoma within hangzhou criteria[J]. Cell Physiol Biochem, 2018, 47(1):293-301.
|
| [18] |
Bruix J, Sherman M. Management of hepatocellular carcinoma: an update[J]. Hepatology, 2011, 53(3):1020-1022.
|
| [19] |
Yang Z, Zhang J, Lu Y, et al. Aspartate aminotransferase-lymphocyte ratio index and systemic immune-inflammation index predict overall survival in HBV-related hepatocellular carcinoma patients after transcatheter arterial chemoembolization[J]. Oncotarget, 2015, 6(40):43090-43098.
|
| [20] |
Conroy G, Salleron J, Belle A, et al. The prognostic value of inflammation-based scores in advanced hepatocellular carcinoma patients prior to treatment with sorafenib[J]. Oncotarget, 2017, 8(56):95853-95864.
|
| [21] |
Passardi A, Scarpi E, Cavanna L, et al. Inflammatory indexes as predictors of prognosis and bevacizumab efficacy in patients with metastatic colorectal cancer[J]. Oncotarget, 2016, 7(22):33210-33219.
|
| [22] |
Ming-Yue T, Zhong-Hong W, Meng-Hui Z, et al. Prognostic value of the systematic immune-inflammation index among patients with operable colon cancer: A retrospective study[J]. Medicine (Baltimore), 2018, 97(45):e13156.
|
| [23] |
Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012[J]. CA Cancer J Clin, 2015, 65(2):87-108.
|
| [24] |
Gerd J, Elisabeth SG, Daniel W, et al. Systemic Immune-Inflammation Index (SII) predicts poor survival in pancreatic cancer patients undergoing resection[J]. J Gastrointest Surg, 2019. doi: 10.1007/s11605-019-04187-z. |
| [25] |
Nicole A, Marie Louise BNB, Laura Chloe W, et al. The wound inflammatory response exacerbates growth of pre-neoplastic cells and progression to cancer[J]? EMBO J, 2015, 34(17):2219-2236.
|
| [26] |
Tanaka Y, Ito S, Isobe K. Vancomycin-sensitive bacteria trigger development of colitis-associated colon cancer by attracting neutrophils[J]. Sci Rep, 2016, 6: 23920.
|
| [27] |
Houghton AM, Rzymkiewicz DH, Gregory AD, et al. Neutrophil elastase-mediated degradation of IRS-1 accelerates lung tumor growth[J]. Nat Med, 2010, 16(2): 219-223.
|
| [28] |
Simon T, Hanan N, Craig M. Neutrophil-mediated tumour angiogenesis: subversion of immune responses to promote tumour growth[J]. Semin Cancer Biol, 2013, 23(3):149-158.
|
| [29] |
Mishalian, Inbal, Bayuh, et al. Tumor-associated neutrophils (TAN) develop pro-tumorigenic properties;during tumor progression[J]. Cancer Immunol Immunother, 2013, 62(11):1745-1756.
|
| [30] |
Ma XM, Sun X, Yang GW, et al. The platelet-to-lymphocyte ratio as a predictor of patient outcomes in ovarian cancer: a meta-analysis[J]. Climacteric, 2017, 20(5):448-455.
|
| [31] |
Yan MJ, Jurasz P. The role of platelets in the tumor microenvironment: From solid tumors to leukemia[J]. Biochim Biophys Acta, 2016, 1863(3):392-400.
|
| [32] |
Weber MR, Zuka M, Lorger M, et al. Activated tumor cell integrinαvβ3 cooperates with platelets to promote extravasation and metastasis from the blood stream[J]. Thromb Res, 2016, 140(Suppl 1:S27-S36.
|
| [33] |
Yibo G, Wei G, Songhua C, et al. Systemic immune-inflammation index (SII) is useful to predict survival outcomes in patients with surgically resected esophageal squamous cell carcinoma[J]. J Cancer, 2019, 10(14):3188-3196.
|
| [34] |
Valerie C, Jinmiao C, Deming L, et al. Chemokine-driven lymphocyte infiltration: an early intratumoural event determining long-term survival in resectable hepatocellular carcinoma[J].Gut, 2012, 61(3):427-438.
|
| [35] |
Jiang D, Liu Y, Hao W, et al. Tumour infiltrating lymphocytes correlate with improved survival in patients with esophageal squamous cell carcinoma[J]. Sci Rep, 2017, 7:44823.
|
| [36] |
Riccardo C, Paolo P, Emanuele C, et al. Nutritional support in cancer patients: A position paper from the Italian Society of Medical Oncology (AIOM) and the Italian Society of Artificial Nutrition and Metabolism (SINPE) [J]. J Cancer, 2016, 7(2):131-135.
|
| [37] |
Hongdian Z, Xiaobin S, Peng R, et al. The predictive value of a preoperative systemic immune-inflammation index and prognostic nutritional index in patients with esophageal squamous cell carcinoma[J]. J Cell Physiol, 2019, 234(2):1794-1802.
|
| [38] |
Johnson PJ, Sarah B, Chiaki K, et al. Assessment of liver function in patients with hepatocellular carcinoma: A new evidence-based approach-the ALBI grade[J]. J Clin Oncol, 2015, 33(6):550-558.
|
| [39] |
Ji F, Fu S, Guo Z, et al. Prognostic significance of preoperative aspartate aminotransferase to neutrophil ratio index in patients with hepatocellular carcinoma after hepatic resection[J]. Oncotarget, 2016, 7(44):72276-72289.
|
| [40] |
Casadei Gardini A, Foschi FG, Conti F, et al. Immune inflammation indicators and ALBI score to predict liver cancer in HCV-patients treated with direct-acting antivirals[J]. Dig Liver Dis, 2019, 51(5):681-688.
|
| [41] |
Zhe H, Fang L. Diagnostic value of serum carbohydrate antigen 19-9 in pancreatic cancer: a meta-analysis[J]. Tumour Biol, 2014, 35(8):7459-7465.
|
| [42] |
Ballehaninna UK, Chamberlain RS. The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal[J]. J Gastrointest Oncol, 2012, 3(2):105-119.
|
| [43] |
Zhang K, Hua YQ, Wang D, et al. Systemic immune-inflammation index predicts prognosis of patients with advanced pancreatic cancer[J].J Transl Med, 2019, 17(1):30.
|